Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TreatMet: Metformin XR Re-challenge in Intolerant Patients
NCT03467763Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), prediabetes, obesity, sponsored by Weill Cornell Medicine. Started Feb 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetesobesity
Beyond the preview
Go deeper on NCT03467763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467763.